A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice

Abstract Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease which affects primarily the joints. Peptides of several proteins have shown an effect in some experimental animal models of RA. We investigated arthritis development in male DBA/1 mice which were injected with bovine co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Clara Wenhart, Hans-Peter Holthoff, Andreas Reimann, Zhongmin Li, Julia Faßbender, Martin Ungerer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/50b17eb211e643d9b23f8b73fc7115ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50b17eb211e643d9b23f8b73fc7115ee
record_format	dspace
spelling	oai:doaj.org-article:50b17eb211e643d9b23f8b73fc7115ee2021-12-02T19:09:31ZA fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice10.1038/s41598-021-95193-22045-2322https://doaj.org/article/50b17eb211e643d9b23f8b73fc7115ee2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95193-2https://doaj.org/toc/2045-2322Abstract Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease which affects primarily the joints. Peptides of several proteins have shown an effect in some experimental animal models of RA. We investigated arthritis development in male DBA/1 mice which were injected with bovine collagen II (bCII) and human fibrinogen (hFib) on days 0 and 21, leading to stable and reproducible disease induction in 100% of immunized mice (FIA-CIA). In a second study, two bCII—derived peptides were given three times in the course of 6 weeks after FIA-CIA induction to test for impact on arthritis. Mice were scored weekly for arthritis and anti-citrullinated peptide antibodies (ACPAs) were determined in the sera taken on days 0, 14, 35, 56 and 84. Histology of the hind paws was performed at the end of the experiment. Intravenous administration of peptide 90578, a novel fructosylated peptide derived from the immunodominant T cell epitope of bCII, at a dosage of 1 mg/kg resulted in significant beneficial effects on clinical outcome parameters and on the arthritis histology scores which was sustained over 12 weeks. Survival tended to be improved in peptide 90578-treated mice. Intravenous administration of pure soluble peptide 90578 without adjuvants is a promising approach to treat RA, with treatment starting at a time when ACPAs are already present. The results complement existing data on peptide “vaccination” of healthy animals, or on treatment using recombinant peptide expressing virus or complex biological compounds.Clara WenhartHans-Peter HolthoffAndreas ReimannZhongmin LiJulia FaßbenderMartin UngererNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Clara Wenhart Hans-Peter Holthoff Andreas Reimann Zhongmin Li Julia Faßbender Martin Ungerer A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
description	Abstract Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease which affects primarily the joints. Peptides of several proteins have shown an effect in some experimental animal models of RA. We investigated arthritis development in male DBA/1 mice which were injected with bovine collagen II (bCII) and human fibrinogen (hFib) on days 0 and 21, leading to stable and reproducible disease induction in 100% of immunized mice (FIA-CIA). In a second study, two bCII—derived peptides were given three times in the course of 6 weeks after FIA-CIA induction to test for impact on arthritis. Mice were scored weekly for arthritis and anti-citrullinated peptide antibodies (ACPAs) were determined in the sera taken on days 0, 14, 35, 56 and 84. Histology of the hind paws was performed at the end of the experiment. Intravenous administration of peptide 90578, a novel fructosylated peptide derived from the immunodominant T cell epitope of bCII, at a dosage of 1 mg/kg resulted in significant beneficial effects on clinical outcome parameters and on the arthritis histology scores which was sustained over 12 weeks. Survival tended to be improved in peptide 90578-treated mice. Intravenous administration of pure soluble peptide 90578 without adjuvants is a promising approach to treat RA, with treatment starting at a time when ACPAs are already present. The results complement existing data on peptide “vaccination” of healthy animals, or on treatment using recombinant peptide expressing virus or complex biological compounds.
format	article
author	Clara Wenhart Hans-Peter Holthoff Andreas Reimann Zhongmin Li Julia Faßbender Martin Ungerer
author_facet	Clara Wenhart Hans-Peter Holthoff Andreas Reimann Zhongmin Li Julia Faßbender Martin Ungerer
author_sort	Clara Wenhart
title	A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
title_short	A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
title_full	A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
title_fullStr	A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
title_full_unstemmed	A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice
title_sort	fructosylated peptide derived from a collagen ii t cell epitope for long-term treatment of arthritis (fia-cia) in mice
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/50b17eb211e643d9b23f8b73fc7115ee
work_keys_str_mv	AT clarawenhart afructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT hanspeterholthoff afructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT andreasreimann afructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT zhongminli afructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT juliafaßbender afructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT martinungerer afructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT clarawenhart fructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT hanspeterholthoff fructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT andreasreimann fructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT zhongminli fructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT juliafaßbender fructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice AT martinungerer fructosylatedpeptidederivedfromacollageniitcellepitopeforlongtermtreatmentofarthritisfiaciainmice
_version_	1718377085813129216

A fructosylated peptide derived from a collagen II T cell epitope for long-term treatment of arthritis (FIA-CIA) in mice

Ejemplares similares